252 related articles for article (PubMed ID: 28861943)
1. Surface-Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy.
Sun X; Han X; Xu L; Gao M; Xu J; Yang R; Liu Z
Small; 2017 Oct; 13(40):. PubMed ID: 28861943
[TBL] [Abstract][Full Text] [Related]
2. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
Rhodes KR; Green JJ
Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
[TBL] [Abstract][Full Text] [Related]
3. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
5. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
[TBL] [Abstract][Full Text] [Related]
6. Paracrine release of IL-2 and anti-CTLA-4 enhances the ability of artificial polymer antigen-presenting cells to expand antigen-specific T cells and inhibit tumor growth in a mouse model.
Zhang L; Wang L; Shahzad KA; Xu T; Wan X; Pei W; Shen C
Cancer Immunol Immunother; 2017 Sep; 66(9):1229-1241. PubMed ID: 28501941
[TBL] [Abstract][Full Text] [Related]
7. Engineering Nanoscale Artificial Antigen-Presenting Cells by Metabolic Dendritic Cell Labeling to Potentiate Cancer Immunotherapy.
Xiao P; Wang J; Zhao Z; Liu X; Sun X; Wang D; Li Y
Nano Lett; 2021 Mar; 21(5):2094-2103. PubMed ID: 33622034
[TBL] [Abstract][Full Text] [Related]
8. Artificial Antigen-Presenting Cells for Immunotherapies.
Siefert AL; Fahmy TM; Kim D
Methods Mol Biol; 2017; 1530():343-353. PubMed ID: 28150213
[TBL] [Abstract][Full Text] [Related]
9. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.
Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O
Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643
[TBL] [Abstract][Full Text] [Related]
10. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8
Hasan AN; Selvakumar A; Shabrova E; Liu XR; Afridi F; Heller G; Riviere I; Sadelain M; Dupont B; O'Reilly RJ
Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21.
Ansén S; Butler MO; Berezovskaya A; Murray AP; Stevenson K; Nadler LM; Hirano N
Clin Cancer Res; 2008 Oct; 14(19):6125-36. PubMed ID: 18829491
[TBL] [Abstract][Full Text] [Related]
12. A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro.
Han H; Peng JR; Chen PC; Gong L; Qiao SS; Wang WZ; Cui ZQ; Yu X; Wei YH; Leng XS
Biochem Biophys Res Commun; 2011 Aug; 411(3):530-5. PubMed ID: 21756876
[TBL] [Abstract][Full Text] [Related]
13. CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.
Bruns H; Bessell C; Varela JC; Haupt C; Fang J; Pasemann S; Mackensen A; Oelke M; Schneck JP; Schütz C
Clin Cancer Res; 2015 May; 21(9):2075-83. PubMed ID: 25593301
[TBL] [Abstract][Full Text] [Related]
14. In situ targeting of dendritic cells by antigen-loaded red blood cells: A novel approach to cancer immunotherapy.
Banz A; Cremel M; Rembert A; Godfrin Y
Vaccine; 2010 Apr; 28(17):2965-72. PubMed ID: 20188177
[TBL] [Abstract][Full Text] [Related]
15. Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic.
Zhang X; Luo M; Dastagir SR; Nixon M; Khamhoung A; Schmidt A; Lee A; Subbiah N; McLaughlin DC; Moore CL; Gribble M; Bayhi N; Amin V; Pepi R; Pawar S; Lyford TJ; Soman V; Mellen J; Carpenter CL; Turka LA; Wickham TJ; Chen TF
Nat Commun; 2021 May; 12(1):2637. PubMed ID: 33976146
[TBL] [Abstract][Full Text] [Related]
16. Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.
Perica K; Bieler JG; Schütz C; Varela JC; Douglass J; Skora A; Chiu YL; Oelke M; Kinzler K; Zhou S; Vogelstein B; Schneck JP
ACS Nano; 2015 Jul; 9(7):6861-71. PubMed ID: 26171764
[TBL] [Abstract][Full Text] [Related]
17. HLA-Class II Artificial Antigen Presenting Cells in CD4
Couture A; Garnier A; Docagne F; Boyer O; Vivien D; Le-Mauff B; Latouche JB; Toutirais O
Front Immunol; 2019; 10():1081. PubMed ID: 31156634
[TBL] [Abstract][Full Text] [Related]
18. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
[TBL] [Abstract][Full Text] [Related]
19. Nanoscale artificial antigen presenting cells for T cell immunotherapy.
Perica K; De León Medero A; Durai M; Chiu YL; Bieler JG; Sibener L; Niemöller M; Assenmacher M; Richter A; Edidin M; Oelke M; Schneck J
Nanomedicine; 2014 Jan; 10(1):119-29. PubMed ID: 23891987
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.
Rhodes KR; Isser A; Hickey JW; Ben-Akiva E; Meyer RA; Kosmides AK; Livingston NK; Tzeng SY; Schneck JP; Green JJ
ACS Appl Mater Interfaces; 2021 Feb; 13(7):7913-7923. PubMed ID: 33573372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]